Showing results for "Industry" in Cancer

We have lost the war on cancer. We spend $150 billion each year treating it, yet - a few innovations notwithstanding - a patient with cancer is as likely to die of it as one was 50 years ago. Most new drugs add mere months to one's life at agonizing physical and financial cost. In The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must.

How does a mere molecule—a chemical structure—become a drug? And how do we know that it works safely? In a one-trillion-dollar pharmaceutical industry with high-stakes profits and perils, battles are raging every day to successfully bring a molecule to its birth: an FDA-approved medicine. In Race for a Remedy, Makhdum Ahmed, MD, an internationally renowned expert in cancer treatment and drug development, takes listeners behind the scenes of the fascinating and intense world of cancer drug development.

The Epstein-Barr virus (EBV) was discovered in 1964. At the time, the very idea of a virus underlying a cancer was revolutionary. Cancer is, after all, not catching. Even now, the idea of a virus causing cancer surprises many people. But Epstein-Barr, named after its discoverers, Sir Anthony Epstein and Dr Yvonne Barr, is fascinating for other reasons, too. Almost everyone carries it, yet it is only under certain circumstances that it produces disease.

The End of the Beginning is a remarkable history of cancer treatment and the evolution of our understanding of its dynamic interplay with the immune system. Through Michael Kinch’s personal experience as a cancer researcher at Washington University and the head of the oncology program at a leading biotechnology company, we witness the incredible accumulation of breakthrough science and its rapid translation into life-saving technologies that have begun to dramatically increase the quality and quantity of life for cancer patients.